On March 6, 2022, SaVi Pharmaceutical Joint Stock Company (SaVipharm) solemnly held the “Ceremony to Receive the Third Class Labor Medal and Inaugurate High-Tech Research and Development Center and National Modern Medicine Distribution System” in Z01-02-03A, Industrial Park of Tan Thuan Export Processing Zone (District 7, Ho Chi Minh City).
SaVipharm is known as an entity that always puts forth strategic vision and investment, implements successful application of science and technology, and attains sustainable achievements. It was established by Meritorious Doctor and Second-Degree Pharmacist Tran Tuu in 2005.
Application of science and technology, research and development
Since its establishment, SaVipharm has consistently spent 5% of total annual revenue on scientific and applied research.
Up to now, SaVipharm has researched and developed 12 groups of medicines and submitted more than 400 sets of generic medicine documents to the Ministry of Health’s Drug Administration of Vietnam. Besides, over 300 new registration numbers for licensed manufacturing have been issued to the company by the Drug Administration of Vietnam. This has contributed to increasing domestic medicines to nearly 55% of total medicine consumption in the market and ensuring sufficient medicines for prevention and treatment of diseases.
SaVipharm is one of the first Vietnamese pharmaceutical companies that is assessed and awarded the Certificate of Science and Technology Company for over 230 products.
Medicine manufacturing and supply
SaVipharm reaches an average growth rate of 20% in production, with an output of 465.6 million and 533.4 million tablets in 2020 and 2021 respectively. The annual revenue of Savipharm increases by over 15% (revenue of Vietnam’s pharmaceutical sector increases by 8-10% per year).
SaVipharm has become a pioneer in exporting medicines to Japan since 2011. In addition, its medicines have been supplied to ASEAN countries like Malaysia, Cambodia and Laos. SaVipharm is one of the first Vietnamese pharmaceutical companies to have obtained both European and Japanese GMP certificates. The OSD pharmaceutical factory of SaVipharm is equipped with SCADA synchronous and up-to-date manufacturing lines and devices and meets two global standards.
The High-Tech Research and Development Center has been invested and operated by SaVipharm with total investment capital of VND200 billion. All the devices and technologies are imported from the Group of Seven (G7), including labs, pilot-scale devices and technologies, and equipment for commercial manufacturing. This Center is designed for researching and developing high quality medicine groups (pellet and microgranular technologies), biomedical products, and new generation medicines for cancer treatment.
National Modern Medicine Distribution System
SaVipharm has invested in one distribution center in Ho Chi Minh City; four supply centers for regions nationwide and branches using WMS, DMS, Barcode and TMS software; automatic sorting and routing lines; and temperature controlled transport vehicles. Therefore, this system has helped improve the quality and effectiveness of medicine supply throughout the nation and received high appreciation from hospitals, local and foreign partners, and pharmacies.
Research and development of high quality medicines
In response to the call and directions of the Prime Minister (who inspected epidemic prevention and control at SaVipharm on July 11, 2021) and utilizing the facilities of the center effectively, the company has overcome challenges and achieved great success in developing high quality medicines for the people’s healthcare.
SaVipharm has successfully researched and invented a medicine for COVID-19 treatment and is completing necessary procedures and conditions to put it into mass production. Furthermore, SaVipharm has studied and developed four types of high quality special medicines that contain microgranular ingredients generated by the equipment and technologies of the High-Tech Research and Development Center. The company is initiating investment, business and manufacturing strategies for the period of 2021-2025, with a vision to 2030, and executing the applied research of vital high-tech medicine groups to satisfy the requirements for epidemic prevention and control according to Vietnam’s disease model. Moreover, SaVipharm is completing legal procedures for commencement of a European GMP-standardized high-tech cancer medicine factory equipped with two automatic OSD medicine manufacturing lines.
Through 15 years of formation and development as well as the solidarity and endeavor of all employees, SaVipharm has achieved remarkable results in science and technology, investment and development, manufacturing and supply and become one of the leading pharmaceutical companies in Vietnam.
